文献速递浆细胞疾病

Modakafusp alfa单药治疗复发/难治性多发性骨髓瘤的2期随机研究

A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma.
PubMed 文献 · Blood · 2025-01-01

Modakafusp alfa是一种将干扰素α靶向CD38+细胞的免疫细胞因子。此项2期剂量优化研究将147例三类难治且既往≥3线治疗的患者按1:1随机分配至每4周120 mg(n=71)或240 mg(n=75)组。因申办方战略原因开发终止且研究提前结束;中位随访7.3和7.6个月时,总缓解率分别为32%和41%,中位无进展生存期分别为4.1和5.3个月。

要点

  • 120 mg组总缓解率32%,240 mg组41%,中位无进展生存期分别为4.1和5.3个月。
  • 未接受过BCMA治疗者总缓解率46%,接受过者为29%。
  • 120 mg组和240 mg组分别有90%和96%的患者发生≥3级治疗相关不良事件。

核心结论

  • 结果证实modakafusp alfa单药对复发/难治性多发性骨髓瘤患者有效。
  • 因申办方战略原因,modakafusp alfa开发终止且研究提前结束。

研究设计与样本

  • 2期剂量优化随机研究,147例三类难治且既往≥3线治疗的患者按1:1随机分配至每4周120 mg(n=71)或240 mg(n=75)组。
  • 120 mg和240 mg为每4周1.5和3 mg/kg的固定剂量等效剂量。
  • 患者既往治疗中位6线;66%为五药暴露,45%既往暴露于抗B细胞成熟抗原(BCMA)治疗。
  • 试验注册号为NCT03215030。

主要发现

  • 120 mg组和240 mg组中位随访分别为7.3和7.6个月。
  • 120 mg组总缓解率32%,240 mg组41%;中位无进展生存期分别为4.1和5.3个月。
  • 未接受过BCMA治疗者总缓解率46%,接受过者为29%。
  • 120 mg组和240 mg组最常见治疗相关不良事件为血小板减少(75%和84%;≥3级55%和61%)和中性粒细胞减少(68%和73%;≥3级56%和68%)。
  • 120 mg组和240 mg组分别有90%和96%的患者发生≥3级治疗相关不良事件,39%和44%发生严重治疗相关不良事件。

关键数值与推荐

  • 此前1/2期试验中,30例接受1.5 mg/kg每4周治疗的患者总缓解率为43%。
  • 本研究120 mg组总缓解率32%,240 mg组41%。
  • 未接受过BCMA治疗者总缓解率46%,接受过者为29%。

局限性

  • 因申办方战略原因,modakafusp alfa开发终止且研究提前结束。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Modakafusp alfa is a first-in-class immunocytokine-directing interferon alfa to CD38+ cells. Our previous phase 1/2 trial identified 2 potential phase 2 doses of modakafusp alfa for patients with relapsed/refractory multiple myeloma (RRMM): 1.5 or 3 mg/kg every 4 weeks. The overall response rate (ORR) among 30 patients treated at 1.5 mg/kg was 43%. This phase 2 dose optimization study randomized 147 patients with triple-class refractory disease and ≥3 previous lines of therapy 1:1 to modakafusp alfa 120 mg (n = 71) or 240 mg (n = 75) every 4 weeks (fixed-dose equivalents of 1.5 and 3 mg/kg every 4 weeks). Patients had received a median of 6 previous lines of therapy; 66% were penta-exposed and 45% had previously been exposed to anti-B-cell maturation antigen (BCMA) therapy. Modakafusp alfa development was discontinued for strategic reasons by the sponsor and the study was terminated early. At median follow-up of 7.3 and 7.6 months in the 120- and 240-mg arms, ORRs were 32% and 41%, and median progression-free survival was 4.1 and 5.3 months, respectively. ORRs were higher in patients who had not received previous BCMA therapy (46% vs 29%). The most common treatment-related adverse events (TEAEs) in the 120- and 240-mg arms were thrombocytopenia (75% and 84%; grade ≥3, 55% and 61%; respectively) and neutropenia (68% and 73%; grade ≥3, 56% and 68%; respectively); 90% and 96% of patients, respectively, experienced grade ≥3 TEAEs; 39% and 44%, respectively, experienced serious TEAEs. Our results confirm the efficacy of single-agent modakafusp alfa for patients with RRMM. This trial was registered at www.clinicaltrials.gov as #NCT03215030.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Holstein SA, Atrash S, Mian H, et al. A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma. Blood. 2025. PMID: 40279508. doi:10.1182/blood.2024027873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。